Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Abasaglar ® (insulin glargin)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
Use of Abasaglar in Paediatric Patients
Abasaglar 100 units/mL solution for injection is indicated for the treatment of diabetes mellitus (DM) in adults, adolescents, and children aged 2 years and above.1
Abasaglar was not studied in children and adolescents 18 years of age or younger.2
Abasaglar can be used in children age 2 years and above, based on the efficacy and safety of Lantus in studies of children age 2 years and above.2
Clinical study safety data for Abasaglar are not available for children under 2 years of age.2
Clinical and Pharmacokinetic Studies of Insulin Glargine in Paediatric Patients
Several clinical studies have demonstrated the efficacy and safety of IG-100 when used for the treatment of T1DM in paediatric patients.3-5
In a PK study of IG-100 in 62 children, aged 2 to 6 years, with T1DM, plasma trough concentrations of IG-100 and its main M1 and M2 metabolites
were similar to those observed in adult patients, and
provided no evidence for accumulation with chronic dosing.6,7
1. Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3. Danne T, Philotheou A, Goldman D, et al. A randomized trial comparing the rate of hypoglycemia -- assessed using continuous glucose monitoring -- in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Pediatr Diabetes. 2013;14(8):593-601. http://dx.doi.org/10.1111/pedi.12051
4. Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care. 2003;26(3):799-804. https://dx.doi.org/10.2337/diacare.26.3.799
5. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K; Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care. 2001;24(11):2005-2006. https://doi.org/10.2337/diacare.24.11.2005
6. Danne T, Becker RH, Ping L, Philotheou A. Insulin glargine metabolite 21A-Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study. Pediatr Diabetes. 2015;16(4):299-304. http://dx.doi.org/10.1111/pedi.12161
7. Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care. 2012;35(12):2626-2630. http://dx.doi.org/10.2337/dc12-0270
Glossary
Abasaglar = Abasaglar® (insulin glargine) 100 units/mL
IG-100 = insulin glargine 100 units/mL
Lantus = Lantus® (insulin glargine) 100 units/mL
M1 = 21A-Gly-human insulin
M2 = 21A-Gly-des-30B-Thr-human insulin
PK = pharmacokinetic
T1DM = type 1 diabetes mellitus
Datum fӧr senaste ӧversyn 2018 M07 24